LT3757107T - 4-okso-3,4-dihidrotieno[3,4-d]piridazino junginiai, kaip aldozės reduktazės inhibitoriai, ir jų panaudojimo būdai - Google Patents

4-okso-3,4-dihidrotieno[3,4-d]piridazino junginiai, kaip aldozės reduktazės inhibitoriai, ir jų panaudojimo būdai

Info

Publication number
LT3757107T
LT3757107T LTEP20188323.8T LT20188323T LT3757107T LT 3757107 T LT3757107 T LT 3757107T LT 20188323 T LT20188323 T LT 20188323T LT 3757107 T LT3757107 T LT 3757107T
Authority
LT
Lithuania
Prior art keywords
dihydrothieno
oxo
methods
reductase inhibitors
aldose reductase
Prior art date
Application number
LTEP20188323.8T
Other languages
English (en)
Inventor
Andrew Wasmuth
Donald W. Landry
Original Assignee
The Trustees Of Columbia University In The City Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of Columbia University In The City Of New York filed Critical The Trustees Of Columbia University In The City Of New York
Publication of LT3757107T publication Critical patent/LT3757107T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Cosmetics (AREA)
LTEP20188323.8T 2016-06-21 2017-06-21 4-okso-3,4-dihidrotieno[3,4-d]piridazino junginiai, kaip aldozės reduktazės inhibitoriai, ir jų panaudojimo būdai LT3757107T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662352784P 2016-06-21 2016-06-21

Publications (1)

Publication Number Publication Date
LT3757107T true LT3757107T (lt) 2023-12-11

Family

ID=60783884

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP20188323.8T LT3757107T (lt) 2016-06-21 2017-06-21 4-okso-3,4-dihidrotieno[3,4-d]piridazino junginiai, kaip aldozės reduktazės inhibitoriai, ir jų panaudojimo būdai
LTEP17816127.9T LT3352754T (lt) 2016-06-21 2017-06-21 Aldozės reduktazės inhibitoriai ir jų naudojimo būdai

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP17816127.9T LT3352754T (lt) 2016-06-21 2017-06-21 Aldozės reduktazės inhibitoriai ir jų naudojimo būdai

Country Status (23)

Country Link
US (5) US10150779B2 (lt)
EP (3) EP3352754B1 (lt)
JP (3) JP6895464B2 (lt)
CN (2) CN115160339B (lt)
AU (3) AU2017281082B2 (lt)
BR (1) BR112018076244A2 (lt)
CA (1) CA3025081A1 (lt)
DK (2) DK3757107T3 (lt)
ES (2) ES2966094T3 (lt)
FI (1) FI3757107T3 (lt)
HK (1) HK1259379A1 (lt)
HR (2) HRP20231563T1 (lt)
HU (2) HUE052101T2 (lt)
IL (3) IL304979A (lt)
LT (2) LT3757107T (lt)
MX (2) MX2018016122A (lt)
PL (1) PL3757107T3 (lt)
PT (2) PT3352754T (lt)
RS (1) RS61239B1 (lt)
SG (2) SG10202012188VA (lt)
SI (2) SI3352754T1 (lt)
WO (1) WO2017223179A1 (lt)
ZA (1) ZA201808506B (lt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
CN115160339B (zh) 2016-06-21 2024-05-14 纽约市哥伦比亚大学理事会 醛糖还原酶抑制剂及其使用方法
BR112020001755A2 (pt) * 2017-07-28 2020-07-21 Applied Therapeutics Inc. composições e métodos para o tratamento de galactosemia
EP3924060A4 (en) * 2019-02-12 2023-03-22 Applied Therapeutics, Inc. METHODS FOR TREATMENT OF SKIN AGING
BR112021019596A2 (pt) 2019-04-01 2021-11-30 Applied Therapeutics Inc Inibidores de aldose redutase
JP2022552831A (ja) * 2019-10-08 2022-12-20 アプライド セラピューティクス, インコーポレイテッド ホスホマンノムターゼ2欠損の処置のためのアルドースレダクターゼ阻害剤
WO2021202523A1 (en) 2020-03-31 2021-10-07 Applied Therapeutics, Inc. Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
AU2021264454A1 (en) 2020-05-01 2022-12-08 Applied Therapeutics, Inc. Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency
US20240033263A1 (en) * 2021-03-18 2024-02-01 Banavara MYLARI Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0189272A3 (en) * 1985-01-17 1987-08-19 Fujisawa Pharmaceutical Co., Ltd. New furanone derivatives, processes for preparation thereof and use thereof
DE3684410D1 (de) 1985-11-07 1992-04-23 Pfizer Heterocyclische oxophthalazinylessigsaeure.
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
CA1299178C (en) 1985-11-07 1992-04-21 Banavara Lakshmana Mylari Heterocyclic oxophtalazinyl acetic acids
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
WO1989006651A1 (en) 1988-01-19 1989-07-27 Pfizer Inc. 1h-indazole-3-acetic acids as aldose reductase inhibitors
US4954629A (en) 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
WO1991009019A1 (en) 1989-12-15 1991-06-27 Pfizer Inc. Substituted oxophthalazinyl acetic acids and analogs thereof
JPH0495025A (ja) 1990-08-08 1992-03-27 Asahi Chem Ind Co Ltd アルドースリダクターゼ阻害剤
EP0662962A1 (en) * 1992-09-28 1995-07-19 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
NZ313896A (en) 1995-08-28 2000-08-25 American Home Prod 4-formyl-2-(naphthalenylmethyl)phenoxyacetic acids or salts and antihyperglycemic agents for the treatment of diabetes mellitus
US6169087B1 (en) 1997-09-23 2001-01-02 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
ES2224632T3 (es) 1998-03-31 2005-03-01 The Institutes For Pharmaceutical Discovery, Inc. Acidos indolalcanoicos sustituidos.
EP0982306A3 (en) 1998-08-21 2000-07-05 Pfizer Products Inc. Polymorph of zopolrestat monohydrate
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
DE60216823T2 (de) 2001-03-30 2007-10-04 Pfizer Products Inc., Groton Zwischenprodukten für die Herstellung von Pyridazinon Aldose Reductase Inhibitoren.
US7314879B2 (en) 2002-01-23 2008-01-01 Eli Lilly And Company Melanocortin receptor agonists
WO2003105864A1 (en) 2002-06-13 2003-12-24 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
CA2489361A1 (en) * 2002-06-14 2003-12-24 Takeda Pharmaceutical Company Limited Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
US20070021366A1 (en) 2004-11-19 2007-01-25 Srivastava Satish K Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use
CN101143868A (zh) 2007-09-04 2008-03-19 北京理工大学 醛糖还原酶抑制剂结构及用途
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
AU2011279058B2 (en) * 2010-07-16 2015-10-01 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
CN102512407B (zh) 2011-11-23 2014-05-21 中山大学 一种β-苯丙氨酸类化合物作为醛糖还原酶抑制剂的应用
CN115160339B (zh) 2016-06-21 2024-05-14 纽约市哥伦比亚大学理事会 醛糖还原酶抑制剂及其使用方法
US11329472B2 (en) 2018-07-20 2022-05-10 Texas Instruments Incorporated Methods and apparatus to prevent undesired triggering of short circuit or over current protection

Also Published As

Publication number Publication date
ZA201808506B (en) 2020-05-27
CN115160339A (zh) 2022-10-11
PT3757107T (pt) 2023-12-14
EP3352754A4 (en) 2019-04-17
JP2019518779A (ja) 2019-07-04
EP3757107B1 (en) 2023-10-25
EP4316603A3 (en) 2024-04-17
CA3025081A1 (en) 2017-12-28
HRP20201905T1 (hr) 2021-01-22
PT3352754T (pt) 2020-12-07
US20200283451A1 (en) 2020-09-10
IL283809B1 (en) 2023-09-01
ES2836500T3 (es) 2021-06-25
SG10202012188VA (en) 2021-01-28
CN109310674B (zh) 2022-07-08
AU2021203801A1 (en) 2021-07-15
EP3757107A1 (en) 2020-12-30
US20180237451A1 (en) 2018-08-23
JP7368419B2 (ja) 2023-10-24
US20190300543A1 (en) 2019-10-03
FI3757107T3 (fi) 2023-12-12
EP3352754B1 (en) 2020-09-02
IL304979A (en) 2023-10-01
EP4316603A2 (en) 2024-02-07
SI3352754T1 (sl) 2021-03-31
AU2017281082B2 (en) 2021-03-18
AU2023204218A1 (en) 2023-07-27
IL263631A (en) 2019-01-31
RU2019101194A3 (lt) 2020-08-31
DK3352754T3 (da) 2020-12-07
JP2023171614A (ja) 2023-12-01
DK3757107T3 (da) 2023-11-27
US10647726B2 (en) 2020-05-12
RS61239B1 (sr) 2021-01-29
HRP20231563T1 (hr) 2024-03-15
HK1259379A1 (zh) 2019-11-29
HUE052101T2 (hu) 2021-04-28
EP3352754A1 (en) 2018-08-01
AU2017281082A1 (en) 2018-12-06
IL263631B (en) 2021-07-29
JP2021130719A (ja) 2021-09-09
SG11201810642XA (en) 2019-01-30
BR112018076244A2 (pt) 2019-03-26
IL283809B2 (en) 2024-01-01
US10150779B2 (en) 2018-12-11
IL283809A (en) 2021-07-29
US20230312599A1 (en) 2023-10-05
WO2017223179A1 (en) 2017-12-28
RU2019101194A (ru) 2020-07-23
LT3352754T (lt) 2021-02-25
MX2021014938A (es) 2022-01-24
PL3757107T3 (pl) 2024-03-18
US10870658B2 (en) 2020-12-22
MX2018016122A (es) 2019-08-01
CN109310674A (zh) 2019-02-05
US11498925B2 (en) 2022-11-15
US20210284652A1 (en) 2021-09-16
HUE064911T2 (hu) 2024-04-28
SI3757107T1 (sl) 2024-02-29
JP6895464B2 (ja) 2021-06-30
CN115160339B (zh) 2024-05-14
AU2021203801B2 (en) 2023-04-06
ES2966094T3 (es) 2024-04-18

Similar Documents

Publication Publication Date Title
LT3757107T (lt) 4-okso-3,4-dihidrotieno[3,4-d]piridazino junginiai, kaip aldozės reduktazės inhibitoriai, ir jų panaudojimo būdai
HUE061989T2 (hu) Szubsztituált tieno[2,3-D]pirimidin származékok mint menin-MLL inhibitorai és alkalmazási eljárások
IL281263B (en) 1h - pyrrolo[2,3-c]pyridine-7(6h)-one and pyrazolo[3,4-c]pyridine-7 (6h)-one as inhibitors of beta proteins
EP3463381A4 (en) NUCLEOTIDE DERIVATIVES AND THEIR METHODS OF USE
PH12017501155A1 (en) Thieno [2,3-c] pyrrol-4-one derivatives as erk inhibitors
HK1250645A1 (zh) 取代的2,3-二氫咪唑並[1,2-c]喹唑啉類化合物的用途
IL262257B (en) 1, 5, -dihydro-4h -pyrazolo[3, 4-d]pyrimidin-4-one and 1, 5, -dihydro-4h -pyrazolo[3, 4-c]pyridin-4-one as pde1 inhibitors
EP3248013A4 (en) Cancer markers and methods of use thereof
GB2560109B (en) Thieno pyrimidine compounds and manufacture of the same
EP3630952A4 (en) MARKERS OF TOTIPOTENCE AND METHOD OF USE
AU2017903306A0 (en) DERIVATIVES OF 4-(IMIDAZO[1,2-b]PYRIDAZIN-3-YL) PYRIMIDIN-2-AMINE AND THEIR USE AS INHIBITORS OF PROTEIN KINASES
AU2016905252A0 (en) Sporting article and methods of use